A detailed history of Hsbc Holdings PLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Hsbc Holdings PLC holds 275,160 shares of EXAS stock, worth $16 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
275,160
Previous 84,218 226.72%
Holding current value
$16 Million
Previous $3.56 Million 426.56%
% of portfolio
0.01%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$42.43 - $70.83 $8.1 Million - $13.5 Million
190,942 Added 226.72%
275,160 $18.7 Million
Q2 2024

Aug 12, 2024

SELL
$41.33 - $74.26 $4.48 Million - $8.05 Million
-108,342 Reduced 56.26%
84,218 $3.56 Million
Q1 2024

May 15, 2024

BUY
$56.27 - $73.77 $6.61 Million - $8.67 Million
117,556 Added 156.73%
192,560 $13.3 Million
Q4 2023

Feb 12, 2024

SELL
$59.06 - $75.72 $88,649 - $113,655
-1,501 Reduced 1.96%
75,004 $5.55 Million
Q3 2023

Nov 13, 2023

SELL
$65.94 - $99.04 $1.89 Million - $2.84 Million
-28,663 Reduced 27.25%
76,505 $5.22 Million
Q2 2023

Aug 11, 2023

BUY
$62.68 - $95.05 $3.32 Million - $5.03 Million
52,925 Added 101.31%
105,168 $9.88 Million
Q1 2023

May 15, 2023

SELL
$47.19 - $70.77 $477,185 - $715,626
-10,112 Reduced 16.22%
52,243 $3.54 Million
Q4 2022

Feb 14, 2023

SELL
$30.35 - $53.15 $1.36 Million - $2.38 Million
-44,805 Reduced 41.81%
62,355 $3.09 Million
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $630,768 - $974,070
19,730 Added 22.57%
107,160 $3.53 Million
Q2 2022

Aug 11, 2022

SELL
$35.61 - $76.23 $1.83 Million - $3.93 Million
-51,506 Reduced 37.07%
87,430 $3.48 Million
Q1 2022

May 16, 2022

BUY
$57.56 - $82.54 $4.09 Million - $5.86 Million
71,056 Added 104.68%
138,936 $9.85 Million
Q4 2021

Feb 11, 2022

SELL
$72.5 - $100.68 $3,407 - $4,731
-47 Reduced 0.07%
67,880 $5.28 Million
Q3 2021

Nov 12, 2021

BUY
$90.24 - $124.05 $1.49 Million - $2.06 Million
16,566 Added 32.25%
67,927 $6.43 Million
Q2 2021

Aug 13, 2021

BUY
$93.66 - $139.27 $1.28 Million - $1.9 Million
13,665 Added 36.25%
51,361 $6.38 Million
Q1 2021

May 14, 2021

SELL
$116.57 - $155.01 $244,330 - $324,900
-2,096 Reduced 5.27%
37,696 $4.97 Million
Q4 2020

Feb 12, 2021

BUY
$99.61 - $142.12 $1.02 Million - $1.46 Million
10,271 Added 34.79%
39,792 $5.27 Million
Q3 2020

Nov 12, 2020

SELL
$72.92 - $102.01 $384,507 - $537,898
-5,273 Reduced 15.15%
29,521 $3.02 Million
Q2 2020

Aug 14, 2020

SELL
$55.75 - $92.75 $1.4 Million - $2.33 Million
-25,093 Reduced 41.9%
34,794 $3.03 Million
Q1 2020

May 15, 2020

BUY
$37.9 - $104.44 $154,669 - $426,219
4,081 Added 7.31%
59,887 $3.48 Million
Q4 2019

Feb 14, 2020

BUY
$77.66 - $99.74 $747,011 - $959,399
9,619 Added 20.83%
55,806 $5.16 Million
Q3 2019

Nov 14, 2019

BUY
$90.37 - $122.49 $1.55 Million - $2.1 Million
17,108 Added 58.83%
46,187 $4.18 Million
Q2 2019

Aug 13, 2019

BUY
$89.51 - $118.04 $470,643 - $620,654
5,258 Added 22.07%
29,079 $3.43 Million
Q1 2019

May 15, 2019

BUY
$61.98 - $96.5 $891,520 - $1.39 Million
14,384 Added 152.42%
23,821 $2.06 Million
Q4 2018

Feb 13, 2019

SELL
$56.04 - $82.66 $185,380 - $273,439
-3,308 Reduced 25.96%
9,437 $595,000
Q3 2018

Nov 13, 2018

BUY
$48.29 - $80.6 $129,948 - $216,894
2,691 Added 26.77%
12,745 $1.01 Million
Q2 2018

Aug 10, 2018

BUY
$37.84 - $69.96 $110,114 - $203,583
2,910 Added 40.73%
10,054 $601,000
Q1 2018

May 11, 2018

SELL
$39.82 - $57.53 $6,371 - $9,204
-160 Reduced 2.19%
7,144 $288,000
Q4 2017

Feb 14, 2018

SELL
$46.49 - $60.51 $1,394 - $1,815
-30 Reduced 0.41%
7,304 $383,000
Q3 2017

Nov 14, 2017

BUY
$37.05 - $47.12 $370 - $471
10 Added 0.14%
7,334 $345,000
Q2 2017

Aug 14, 2017

BUY
N/A
7,324
7,324 $259,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.